PepGen (PEPG) announced initial clinical data from the five and ten mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1. Mean splicing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback